PI3Kα Pathway Inhibition With Doxorubicin Treatment Results in Distinct Biventricular Atrophy and Remodeling With Right Ventricular Dysfunction

BACKGROUND: Cancer therapies inhibiting PI3Kα (phosphoinositide 3‐kinase‐α)–dependent growth factor signaling, including trastuzumab inhibition of HER2 (Human Epidermal Growth Factor Receptor 2), can cause adverse effects on the heart. Direct inhibition of PI3Kα is now in clinical trials, but the ef...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Am Heart Assoc
Glavni autori: McLean, Brent A., Patel, Vaibhav B., Zhabyeyev, Pavel, Chen, Xueyi, Basu, Ratnadeep, Wang, Faqi, Shah, Saumya, Vanhaesebroeck, Bart, Oudit, Gavin Y.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2019
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6512135/
https://ncbi.nlm.nih.gov/pubmed/31039672
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.118.010961
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items